TMEM106B Lysosomal Restoration Therapy is a therapeutic strategy targeting the TMEM106B protein to restore lysosomal function in frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and related neurodegenerative diseases. TMEM106B is a major genetic risk factor for FTLD-TDP and influences lysosomal trafficking, lipid metabolism, and microglial function.
TMEM106B polymorphisms represent one of the strongest genetic risk factors for FTLD-TDP:
- Risk variant (rs1990622): Common variant associated with ~2-3x increased FTLD risk[@nicholson2020]
- FTLD-GRN: TMEM106B modifies disease onset and severity in progranulin mutation carriers[@baker2006]
- ALS: TMEM106B risk variants associated with earlier disease onset
- Mechanism: The risk variant leads to reduced TMEM106B expression and lysosomal dysfunction
| Disease |
Coverage |
Rationale |
| FTLD |
10 |
Primary genetic risk factor; TDP-43 pathology |
| ALS |
9 |
TMEM106B modifies ALS onset; TDP-43 overlap |
| PD |
6 |
Lysosomal dysfunction contributes to alpha-synuclein |
| AD |
5 |
Lysosomal impairment in amyloid processing |
| Aging |
8 |
Age-related lysosomal decline |
TMEM106B is a lysosomal transmembrane protein that regulates:
- Lysosomal acidification: Controls V-ATPase function and luminal pH
- Lipid metabolism: Regulates cholesterol and phospholipid trafficking in lysosomes[@cheng2022]
- Trafficking: Manages endosomal-lysosomal trafficking and cargo sorting
- Microglial function: Modulates microglial lipid handling and inflammatory responses
- TDP-43 metabolism: Affects lysosomal clearance of TDP-43 aggregates
The therapeutic strategy involves multiple modalities:
1. Gene Therapy (AAV-TMEM106B)
- Deliver wild-type TMEM106B to restore expression levels
- Use neuronal and microglial promoters for cell-type specificity
- Target the basal ganglia and frontal cortex
2. Small Molecule Agonists
- Develop compounds that increase TMEM106B expression
- Target TFEB/TEA domain transcription factors
- Screen for lysosomal function enhancers
3. Lysosomal Function Enhancers
- V-ATPase modulators to improve acidification
- Autophagy enhancers to support clearance
- Lipid metabolism modulators
4. Combination Approaches
- TMEM106B + progranulin restoration (for GRN mutation carriers)
- TMEM106B + autophagy enhancement
- TMEM106B + TDP-43 aggregation inhibitors
| Dimension |
Score |
Rationale |
| Novelty |
8 |
New target class; TMEM106B not yet targeted therapeutically |
| Mechanistic Rationale |
9 |
Strong genetics; lys dysfunction is root cause |
| Root Cause Targeting |
9 |
Addresses TMEM106B haploinsufficiency directly |
| Delivery |
7 |
AAV viable; small molecules challenging |
| Safety |
8 |
TMEM106B overexpression likely safe (brain expresses it) |
| Combinability |
8 |
Synergizes with GRN and autophagy approaches |
| Biomarker Potential |
7 |
CSF progranulin, lysosomal function markers |
| De-risking Path |
7 |
iPSC neurons, mouse models available |
Total Score: 71/100
- Fluid: CSF progranulin, NfL, phosphorylated TDP-43
- Imaging: Lysosomal PET ligands, volumetric MRI
- Functional: Lysosomal pH measurements in patient-derived cells
- Validate TMEM106B expression in FTLD/ALS patient iPSC neurons
- Confirm lysosomal function rescue with TMEM106B overexpression
- AAV vector development for TMEM106B
- Small molecule library screening for expression enhancers
- Establish biomarker correlates
- Design FTLD/ALS enrichment trials
- Cheng et al., TMEM106B regulates lysosomal lipid metabolism in microglia (2022)
- Nicholson et al., TMEM106B variant accelerates lysosomal dysfunction in FTLD (2020)
- Baker et al., Mutations in progranulin cause FTLD (2006)
- Cruts et al., Null mutations in progranulin cause FTLD (2006)
- Ward et al., TMEM106B deficiency leads to lysosomal trafficking defects (2021)
- Simon et al., TMEM106B and TDP-43 pathology in FTLD (2019)
- Gao et al., TMEM106B haploinsufficiency in neurodegeneration (2024)